Wedbush reiterated their outperform rating on shares of Oculis (NASDAQ:OCS – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $29.00 price objective on the stock.
Other equities research analysts have also issued research reports about the stock. Robert W. Baird upped their price objective on shares of Oculis from $58.00 to $64.00 in a report on Wednesday, August 9th. Bank of America boosted their price objective on Oculis from $23.00 to $24.00 and gave the stock a buy rating in a research report on Tuesday, August 29th. HC Wainwright reissued a buy rating and issued a $29.00 target price on shares of Oculis in a report on Wednesday, August 30th. Finally, Stifel Nicolaus assumed coverage on Oculis in a report on Wednesday, October 4th. They set a buy rating and a $35.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of Buy and a consensus target price of $34.00.
Oculis Stock Performance
Oculis (NASDAQ:OCS – Get Free Report) last announced its earnings results on Tuesday, August 29th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The business had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.28 million. Research analysts predict that Oculis will post -2.91 EPS for the current fiscal year.
Institutional Trading of Oculis
Institutional investors have recently bought and sold shares of the stock. Barclays PLC acquired a new stake in Oculis in the 2nd quarter valued at about $44,000. Wolverine Asset Management LLC bought a new position in Oculis in the 3rd quarter valued at $77,000. Ergoteles LLC acquired a new stake in shares of Oculis in the 2nd quarter valued at $247,000. HRT Financial LP bought a new stake in shares of Oculis during the first quarter worth approximately $178,000. Finally, Nan Fung Group Holdings Ltd bought a new stake in Oculis in the first quarter valued at approximately $4,838,000. Institutional investors and hedge funds own 14.28% of the company’s stock.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
- Five stocks we like better than Oculis
- Health Care Stocks Explained: Why You Might Want to Invest
- The most upgraded stocks in November have two things in common
- How to Invest in Virtual Reality
- Monday.com rocked earnings like it’s the weekend
- Crypto vs Stocks: How to Choose Your Investments
- Plan to own one retailer? Make it this one
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.